Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib plus avelumab in refractory advanced NEN G3
2021-000986-34Phase 2Active
- Sponsor
- University Medical Center Mainz
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and avelumab in apudoma (NET) and neuroendocrine carcinoma (NEC), sponsored by University Medical Center Mainz. Primary endpoint: Disease control rate at 16 weeks. Started Sep 2021; status: active.
02
Drugs
cabozantinibavelumab
03
Conditions
apudoma (NET)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2021-000986-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000986-34.